Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fosravuconazole additional treatment for refractory onychomycosis
jRCTs031200047Completed
- Sponsor
- Sato Pharmaceutical
- Start
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of fosravuconazole in onychomycosis (3 arms), sponsored by Sato Pharmaceutical. Primary endpoint: Complete cure rate at Week 72. Started Jul 2020; status: completed.
02
Drugs
fosravuconazole
03
Conditions
onychomycosis
Beyond the preview
Go deeper on jRCTs031200047.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031200047.